
Braidwell LP
About Braidwell LP’s 13F portfolio
Braidwell LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Braidwell LP reported $2.7B across 86 US-listed positions (). Its largest position is CARIS LIFE SCIENCES INC (CAI) at 5.4% of the reported book, and its ten biggest holdings make up 32% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: CAI CARIS LIFE SCIENCES INC | $19.50 −2.21% | 5.4% | 8.3M | $147.1M |
| 2 | NYSE: HNGE HINGE HEALTH INC | $114.53 +0.10% | 4.1% | 1.3M | $110.4M |
| 3 | NYSE: GKOS GLAUKOS CORP | $233.08 −4.18% | 3.1% | 592K | $82.7M |
| 4 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | $41.37 −1.59% | 3.0% | 2.0M | $81.1M |
| 5 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | $101.46 +8.15% | 2.9% | 879K | $78.1M |
| 6 | NASDAQ: IRTC IRHYTHM HOLDINGS INC | $94.87 +5.80% | 2.9% | 654K | $77.8M |
| 7 | NASDAQ: NEO NEOGENOMICS INC | $15.29 +0.26% | 2.7% | 4.9M | $71.8M |
| 8 | NASDAQ: KOD KODIAK SCIENCES INC | $97.81 +1.04% | 2.6% | 1.8M | $69.6M |
| 9 | NASDAQ: XENE XENON PHARMACEUTICALS INC | $37.75 −2.66% | 2.5% | 1.1M | $68.3M |
| 10 | — ALPHATEC HLDGS INC | — — | 2.4% | 69.1M | $66.2M |
| 11 | NASDAQ: GLUE MONTE ROSA THERAPEUTICS INC | $9.07 0.00% | 2.2% | 2.5M | $59.3M |
| 12 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | $83.98 −3.45% | 2.1% | 595K | $58.0M |
| 13 | NASDAQ: NBIX NEUROCRINE BIOSCIENCES INC | $162.86 −1.84% | 2.1% | 336K | $56.7M |
| 14 | NASDAQ: ATEC ALPHATEC HLDGS INC | $7.06 +1.73% | 2.1% | 6.5M | $56.5M |
| 15 | NASDAQ: GENB GENERATE BIOMEDICINES INC | — — | 2.0% | 3.3M | $55.4M |
| 16 | NASDAQ: MRVI MARAVAI LIFESCIENCES HLDGS I | $7.38 +1.37% | 2.0% | 8.7M | $54.3M |
| 17 | NASDAQ: KRYS KRYSTAL BIOTECH INC | $315.34 +5.62% | 1.8% | 129K | $47.9M |
| 18 | NYSE: HUM HUMANA INC | $385.78 −12.98% | 1.7% | 115K | $45.5M |
| 19 | NYSE: TMO THERMO FISHER SCIENTIFIC INC | $692.74 +0.87% | 1.7% | 89K | $44.8M |
| 20 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | $121.13 −0.32% | 1.6% | 378K | $43.4M |
| 21 | NASDAQ: RYTM RHYTHM PHARMACEUTICALS INC | $119.04 +2.08% | 1.6% | 381K | $42.3M |
| 22 | NASDAQ: DMRA DAMORA THERAPEUTICS INC | — — | 1.6% | 1.6M | $42.1M |
| 23 | NASDAQ: ACAD ACADIA PHARMACEUTICALS INC | $17.83 −2.67% | 1.5% | 1.6M | $41.7M |
| 24 | NASDAQ: BTSG BRIGHTSPRING HEALTH SVCS INC | $68.34 −2.13% | 1.5% | 597K | $41.6M |
| 25 | NASDAQ: TMDX TRANSMEDICS GROUP INC | $96.43 +2.68% | 1.5% | 610K | $40.5M |
Showing 1–25 of 86 positions on this page reported in this 13F.
- Healthcare90%
- AddedCAICARIS LIFE SCIENCES INC+3.1%$147.1M
- AddedIRTCIRHYTHM HOLDINGS INC+7.2%$77.8M
- Added—ALPHATEC HLDGS INC+12.2%$66.2M
- AddedATECALPHATEC HLDGS INC+201%$56.5M
- NewHUMHUMANA INC—$45.5M
- AddedKYMRKYMERA THERAPEUTICS INC+12.0%$43.4M
- AddedRYTMRHYTHM PHARMACEUTICALS INC+22.7%$42.3M
- AddedDMRADAMORA THERAPEUTICS INC+81.1%$42.1M
- AddedTMDXTRANSMEDICS GROUP INC+85.1%$40.5M
- AddedCLYMCLIMB BIO INC+82.9%$36.5M
- ReducedHNGEHINGE HEALTH INC−8.6%$110.4M
- ReducedGKOSGLAUKOS CORP−22.5%$82.7M
- ReducedEWTXEDGEWISE THERAPEUTICS INC−14.9%$81.1M
- ReducedSYRESPYRE THERAPEUTICS INC−5.7%$78.1M
- ReducedNEONEOGENOMICS INC−12.4%$71.8M
- ReducedKODKODIAK SCIENCES INC−1.7%$69.6M
- ReducedXENEXENON PHARMACEUTICALS INC−15.5%$68.3M
- ReducedGLUEMONTE ROSA THERAPEUTICS INC−23.5%$59.3M
- ReducedDNTHDIANTHUS THERAPEUTICS INC−33.9%$58.0M
- ReducedNBIXNEUROCRINE BIOSCIENCES INC−48.4%$56.7M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | AMAN Amanat Acquisition Corp. | 13G | 9.3% | 700K | Filed 14 AUG 2026 |
Showing all 1 disclosed stakes.
Reading Braidwell LP’s 13F portfolio
Braidwell LP’s $2.7B 13F book is spread across 86 reported positions and is moderately diversified, the ten largest names accounting for 32%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are CAI, HNGE, GKOS, EWTX and SYRE, led by CARIS LIFE SCIENCES INC (CAI) at 5.4% of the portfolio. The heaviest sector exposure is Healthcare (90%).
What Braidwell LP changed last quarter
Between 2026-03-31 and Q2 2026, Braidwell LP was a net seller: it opened 24 new positions and added to 21 more, while trimming 36 and closing 26 outright. Against a 86-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was CARIS LIFE SCIENCES INC (CAI), and its biggest reduction was HINGE HEALTH INC (HNGE).
What a 13F does and doesn’t reveal
A 13F captures only Braidwell LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Braidwell LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Braidwell LP's profile on this page is built directly from those filings.
How current is the 13F data on Braidwell LP's page?
It reflects Braidwell LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Braidwell LP files its next quarterly report, this page refreshes automatically.
Can I see Braidwell LP's complete list of holdings?
This page highlights Braidwell LP's largest positions rather than all 86 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Braidwell LP's filings.
Does a 13F show everything Braidwell LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Braidwell LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Braidwell LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

